Initiator Pharma A/S (INIT.ST)
Initiator Pharma A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Copenhagen, CR, DK. The stock last traded at $2.08, down 2.80% on the session, giving a market capitalisation of $142.4M. Its beta of 0.10 implies it has historically moved less than the broad market.
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.
Initiator Pharma A/S is most often compared with the following Healthcare names: